Innovating science and practice - Broadening the understanding of PCSK9i mAb

1-3 of 3

• 

  RestartResume

  Initiating PCSK9 mAb after ACS: When and how to start?

  RestartResume

  Initiating PCSK9 mAb after ACS: When and how to start?

  Innovating science and practice - Broadening the understanding of PCSK9i mAb

  Initiating PCSK9 mAb after ACS: When and how to start?

  Prof. Wouter Jukema, MD, PhD; Pasquale Perrone-Filardi, MD, PhD

  • 

    

    Prof. Wouter Jukema, MD, PhD

  • 

    

    Pasquale Perrone-Filardi, MD, PhD

• 

  RestartResume

  Effects of intensive lipid lowering on coronary plaque characteristics

  RestartResume

  Effects of intensive lipid lowering on coronary plaque characteristics

  Innovating science and practice - Broadening the understanding of PCSK9i mAb

  Effects of intensive lipid lowering on coronary plaque characteristics

  Prof. Lorenz Räber, MD, PhD; Prof. Stephen Nicholls, MD

  • 

    

    Prof. Lorenz Räber, MD, PhD

  • 

    

    Prof. Stephen Nicholls, MD

• 

  RestartResume

  Real-world evidence with PCSK9i mAb; implications and lessons for current clinical use

  RestartResume

  Real-world evidence with PCSK9i mAb; implications and lessons for current clinical use

  Innovating science and practice - Broadening the understanding of PCSK9i mAb

  Real-world evidence with PCSK9i mAb; implications and lessons for current clinical use

  Raul Santos, MD, PhD; Prof. Maciej Banach, MD, PhD

  • 

    

    Raul Santos, MD, PhD

  • 

    

    Prof. Maciej Banach, MD, PhD